Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5N1 Cohort for Expanded Research

(NASDAQ:MGRX), Dallas, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”), a company focused on developing, marketing, and selling a variety of men's wellness products and services via a secure telemedicine platform, today announced significant progress in its ongoing H1N1 efficacy study conducted by Vipragen Biosciences (“Vipragen”), an AAALAC-accredited […]

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

(NASDAQ:AGIO), CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 13, 2025, at 8:00 a.m. ET to report its fourth quarter

Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo(R) (cemiplimab)

(NasdaqGM:IMRX), – Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – – Data presented at AACR 2023 supports dual-targeting potential of IMM-1-104 in combination with anti-PD-1 – CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a

Peloton Interactive, Inc. Reports Second Quarter Fiscal 2025 Financial Results

(NASDAQ:PTON), NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) — Peloton Interactive, Inc. (Nasdaq: PTON) has announced its financial results for the second quarter fiscal 2025. Please visit the Peloton investor relations website to view the shareholder letter. Today, the company will host a conference call and live audio webcast to discuss the results at 8:30

Voyager to Present at Oppenheimer 25th Annual Healthcare Life Sciences Conference

(NASDAQ:VYGR), LEXINGTON, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will participate in a fireside chat at the Oppenheimer 25th Annual Healthcare Life Sciences Conference at 2:40 p.m. ET on February 11, 2025. A webcast of the presentation will be

Restaurant sales projected to grow by a mere 0.8% in 2025 amid tariff threats, changes to immigration and low consumer confidence

Toronto, Feb. 06, 2025 (GLOBE NEWSWIRE) — Foodservice sales are forecast to grow by 3.7% in the first quarter of 2025, thanks to a significant boost from the GST and HST holiday, but restaurants are still facing economic headwinds after a weak third quarter, according to Restaurants Canada's latest Quarterly Report. Quarterly Report at a

Microbix Schedules Release of Results for Q1 Fiscal 2025

(TSX:MBX),(OTC US:MBXBF),(Other OTC:MBXBF), MISSISSAUGA, Ontario, Feb. 06, 2025 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix(R)), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements and management disclosure and analysis for its first quarter of fiscal 2025 ended December 31, 2024 (“Q1 2025“) prior to

Manhattan Bridge Capital, Inc. Declares Quarterly Dividend

(NASDAQ:LOAN), GREAT NECK, N.Y., Feb. 06, 2025 (GLOBE NEWSWIRE) — Manhattan Bridge Capital, Inc. (NASDAQ: LOAN) announced today that its board of directors has declared a quarterly dividend of $0.115 per share to be paid to all shareholders of record on April 8, 2025. The dividend will be paid on April 15, 2025. Contact:Assaf Ran,

BioXcel Therapeutics Announces Reverse Stock Split

(NASDAQ:BTAI), NEW HAVEN, Conn., Feb. 06, 2025 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it will effect a 1-for-16 reverse stock split of its common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time on

Tecnoglass Sets Date for Fourth Quarter and Full Year 2024 Results

(NYSE:TGLS), Miami, FL, Feb. 06, 2025 (GLOBE NEWSWIRE) — Tecnoglass, Inc. (NYSE: TGLS) (“Tecnoglass” or the “Company”), a leading producer of high-end aluminum and vinyl windows and architectural glass for the global residential and commercial end markets, today announced it will release financial results for the fourth quarter and full year 2024 before the market

Scroll to Top